Morgan Stanley initiates Immix Biopharma with overweight rating
UKPulse Markets Desk
Morgan Stanley has initiated coverage of Immix Biopharma stock with an overweight rating, according to a report dated 20 October 2026.
- Morgan Stanley initiated Immix Biopharma stock with an overweight rating.
- The initiation was reported on 20 October 2026.
Morgan Stanley has initiated coverage of Immix Biopharma stock with an overweight rating, according to a report published on 20 October 2026.
The rating was disclosed in a stock-market news item from Investing.com UK. No further details of the initiation, including any price target, were provided in the available evidence.